Journal
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
Volume 7, Issue 1, Pages 22-32Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756285613501576
Keywords
capsaicin; capsaicinoids; neuropathic pain; TRPV1
Categories
Funding
- Ameritox
- Endo Pharmaceuticals
- INSYS Therapeutics
- Zogenix Pharmaceuticals
- Grunenthal
Ask authors/readers for more resources
The treatment of neuropathic pain is difficult. Oral pharmaceuticals have significant side effects, and treatment efficacy tends to be modest. The use of topical analgesics reduces the potential for systemic side effects and allows direct application of medications to the area of pain. The natural spicy substance, capsaicin, has historically been known for its topical use. Capsaicin, once applied to the skin, causes a brief initial sensitization followed by a prolonged desensitization of the local pain nerves. This occurs through stimulation of the transient receptor potential vanilloid-1 (TRPV1) expressing pain nerve fibers. While low-dose capsaicin has not resulted in good efficacy, the larger dose 8% topical capsaicin has had some of the best data currently available in the treatment of post-herpetic neuralgia (PHN) and other neuropathic conditions. This paper discusses the data currently existing for capsaicin 8% in the treatment of PHN. It further reviews data for the low-dose capsaicin products and the current status in the development of other capsaicinoids, e.g. resiniferotoxin, and high-concentration liquid capsaicin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available